Harmonization of pipeline for preclinical multicenter MRI biomarker discovery in a rat model of post-traumatic epileptogenesis.


Journal

Epilepsy research
ISSN: 1872-6844
Titre abrégé: Epilepsy Res
Pays: Netherlands
ID NLM: 8703089

Informations de publication

Date de publication:
02 2019
Historique:
received: 15 10 2018
revised: 12 12 2018
accepted: 05 01 2019
pubmed: 15 1 2019
medline: 19 6 2019
entrez: 15 1 2019
Statut: ppublish

Résumé

Preclinical imaging studies of posttraumatic epileptogenesis (PTE) have largely been proof-of-concept studies with limited animal numbers, and thus lack the statistical power for biomarker discovery. Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx) is a pioneering multicenter trial investigating preclinical imaging biomarkers of PTE. EpiBios4Rx faced the issue of harmonizing the magnetic resonance imaging (MRI) procedures and imaging data metrics prior to its execution. We present here the harmonization process between three preclinical MRI facilities at the University of Eastern Finland (UEF), the University of Melbourne (Melbourne), and the University of California, Los Angeles (UCLA), and evaluate the uniformity of the obtained MRI data. Adult, male rats underwent a lateral fluid percussion injury (FPI) and were followed by MRI 2 days, 9 days, 1 month, and 5 months post-injury. Ex vivo scans of fixed brains were conducted 7 months post-injury as an end point follow-up. Four MRI modalities were used: T2-weighted imaging, multi-gradient-echo imaging, diffusion-weighted imaging, and magnetization transfer imaging, and acquisition parameters for each modality were tailored to account for the different field strengths (4.7 T and 7 T) and different MR hardwares used at the three participating centers. Pilot data collection resulted in comparable image quality across sites. In interim analysis (of data obtained by April 30, 2018), the within-site variation of the quantified signal properties was low, while some differences between sites remained. In T2-weighted images the signal-to-noise ratios were high at each site, being 35 at UEF, 48 at Melbourne, and 32 at UCLA (p < 0.05). The contrast-to-noise ratios were similar between the sites (9, 10, and 8, respectively). Magnetization transfer ratio maps had identical white matter/ gray matter contrast between the sites, with white matter showing 15% higher MTR than gray matter despite different absolute MTR values (MTR both in white and gray matter was 3% lower in Melbourne than at UEF, p < 0.05). Diffusion-weighting yielded different degrees of signal attenuation across sites, being 83% at UEF, 76% in Melbourne, and 80% at UCLA (p < 0.05). Fractional anisotropy values differed as well, being 0.81 at UEF, 0.73 in Melbourne, and 0.84 at UCLA (p < 0.05). The obtained values in sham animals showed low variation within each site and no change over time, suggesting high repeatability of the measurements. Quality control scans with phantoms demonstrated stable hardware performance over time. Timing of post-TBI scans was designed to target specific phases of the dynamic pathology, and the execution at different centers was highly accurate. Besides a few outliers, the 2-day scans were done within an hour from the target time point. At day 9, most animals were scanned within an hour from the target time point, and all but 2 outliers within 24 h from the target. The 1-month post-TBI scans were done within 31 ± 3 days. MRI procedures and animal physiology during scans were similar between the sites. Taken together, the 10% inter-site difference in FA and 3% difference in MTR values should be included into analysis as a covariate or balanced out in post-processing in order to detect disease-related effects on brain structure at the same scale. However, for a MRI biomarker for post-traumatic epileptogenesis to have realistic chance of being successfully translated to validation in clinical trials, it would need to be a robust TBI-induced structural change which tolerates the inter-site methodological variability described here.

Identifiants

pubmed: 30641351
pii: S0920-1211(18)30476-5
doi: 10.1016/j.eplepsyres.2019.01.001
pmc: PMC6818721
mid: NIHMS1055133
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

46-57

Subventions

Organisme : NICHD NIH HHS
ID : U54 HD087101
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS100064
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

Neurology. 2002 Nov 12;59(9 Suppl 5):S21-6
pubmed: 12428028
Neuroscience. 2017 Sep 1;358:277-299
pubmed: 28688882
J Neurotrauma. 2013 Jul 15;30(14):1305-9
pubmed: 23469770
Front Neurosci. 2015 Apr 22;9:128
pubmed: 25954146
Neuroscience. 2006 Jun 30;140(2):685-97
pubmed: 16650603
Front Neurol. 2018 Jun 11;9:438
pubmed: 29942282
J Neuroinflammation. 2016 Oct 11;13(1):264
pubmed: 27724914
Neurobiol Dis. 2019 Mar;123:42-58
pubmed: 29782966
Neuroimage. 2016 Jun;133:129-143
pubmed: 26975556
Front Endocrinol (Lausanne). 2018 Apr 25;9:176
pubmed: 29922224
Epilepsia. 2003;44(s10):11-7
pubmed: 14511389
Neuropharmacology. 2016 Nov;110(Pt B):654-659
pubmed: 25963414
Brain Imaging Behav. 2018 Feb;12(1):284-295
pubmed: 28176263
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
Neuropathol Appl Neurobiol. 2018 Feb;44(1):91-111
pubmed: 28977690
Epilepsia. 2005 Apr;46(4):470-2
pubmed: 15816939
Am J Physiol Heart Circ Physiol. 2016 Nov 1;311(5):H1118-H1131
pubmed: 27614225
Epilepsia. 2013 Aug;54 Suppl 4:61-9
pubmed: 23909854
FP Essent. 2016 Dec;451:25-30
pubmed: 27936532
Cell Mol Neurobiol. 2017 May;37(4):571-585
pubmed: 27383839
Neurotherapeutics. 2014 Apr;11(2):286-96
pubmed: 24554454
PLoS One. 2010 Sep 28;5(9):null
pubmed: 20927408
J Neurotrauma. 2017 Jul 1;34(13):2109-2118
pubmed: 28152648
J Neurotrauma. 2009 Apr;26(4):481-95
pubmed: 19196176
J Neurotrauma. 2007 May;24(5):753-65
pubmed: 17518531
Injury. 2017 Dec;48(12):2675-2682
pubmed: 29061477

Auteurs

Riikka Immonen (R)

A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, FIN-70211 Kuopio, Finland. Electronic address: riikka.immonen@uef.fi.

Gregory Smith (G)

Department of Neurology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90095, USA.

Rhys D Brady (RD)

Departments of Neuroscience and Neurology, Central Clinical School, Alfred Health, Monash University, Melbourne, Victoria, Australia; Departments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.

David Wright (D)

Departments of Neuroscience and Neurology, Central Clinical School, Alfred Health, Monash University, Melbourne, Victoria, Australia.

Leigh Johnston (L)

Florey Institute of Neuroscience and Mental Health, Parkville, VIC 3052, Australia.

Neil G Harris (NG)

Department of Neurology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90095, USA.

Eppu Manninen (E)

A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, FIN-70211 Kuopio, Finland.

Raimo Salo (R)

A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, FIN-70211 Kuopio, Finland.

Craig Branch (C)

Albert Einstein College of Medicine, New York, NY 10461, USA.

Dominique Duncan (D)

USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA 90033, USA.

Ryan Cabeen (R)

USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA 90033, USA.

Xavier Ekolle Ndode-Ekane (XE)

A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, FIN-70211 Kuopio, Finland.

Cesar Santana Gomez (CS)

Department of Neurology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90095, USA.

Pablo M Casillas-Espinosa (PM)

Departments of Neuroscience and Neurology, Central Clinical School, Alfred Health, Monash University, Melbourne, Victoria, Australia; Departments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.

Idrish Ali (I)

Departments of Neuroscience and Neurology, Central Clinical School, Alfred Health, Monash University, Melbourne, Victoria, Australia; Departments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.

Sandy R Shultz (SR)

Departments of Neuroscience and Neurology, Central Clinical School, Alfred Health, Monash University, Melbourne, Victoria, Australia; Departments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.

Pedro Andrade (P)

A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, FIN-70211 Kuopio, Finland.

Noora Puhakka (N)

A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, FIN-70211 Kuopio, Finland.

Richard J Staba (RJ)

Department of Neurology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90095, USA.

Terence J O'Brien (TJ)

Departments of Neuroscience and Neurology, Central Clinical School, Alfred Health, Monash University, Melbourne, Victoria, Australia; Departments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.

Arthur W Toga (AW)

USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA 90033, USA.

Asla Pitkänen (A)

A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, FIN-70211 Kuopio, Finland.

Olli Gröhn (O)

A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, FIN-70211 Kuopio, Finland.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH